8IJZ

anti-VEGF mutant

8IJZ の概要

• エントリーDOI: 10.2210/pdb8ijz/pdb
• 分子名称: anti-VEGF nanobody (1 entity in total)
• 機能のキーワード: anti-vegf, nanobody, antitumor protein, antitumor protein-immune system
• 由来する生物種: Homo sapiens
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 13731.32

構造登録者

Qian, F.,Zhu, S.Q. (登録日: 2023-02-28, 公開日: 2023-12-27, 最終更新日: 2024-10-09)

主引用文献

Zhu, S.,Fan, S.,Tang, T.,Huang, J.,Zhou, H.,Huang, C.,Chen, Y.,Qian, F.
Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
Bioeng Transl Med, 8:e10523-e10523, 2023

PubMed Abstract: Wet age-related macular degeneration (wet AMD) is the most common cause of blindness, and chronic intravitreal injection of anti-vascular endothelial growth factor (VEGF) proteins has been the dominant therapeutic approach. Less intravitreal injection and a prolonged inter-injection interval are the main drivers behind new wet AMD drug innovations. By rationally engineering the surface residues of a model anti-VEGF nanobody, we obtained a series of anti-VEGF nanobodies with identical protein structures and VEGF binding affinities, while drastically different crystallization propensities and crystal lattice structures. Among these nanobody crystals, the 222 lattice appeared to be denser and released protein slower than the 1 lattice, while nanobody crystals embedding zinc coordination further slowed the protein release rate. The polymorphic protein crystals could be a potentially breakthrough strategy for chronic intravitreal administration of anti-VEGF proteins.

PubMed: 38023710
DOI: 10.1002/btm2.10523

実験手法

ELECTRON CRYSTALLOGRAPHY (2.1 Å)